Conjugates of Prostate-Specific Membrane Antigen Ligands with Antitumor Drugs

Conjugates of Prostate-Specific Membrane Antigen Ligands with Antitumor Drugs

Conjugates for targeted delivery that are based on low-molecular-mass prostate specific membrane antigen (PSMA) inhibitors are widely used and developed because of the deficiencies of existing methods for treating and diagnosing prostate cancer. The major classes of low-molecular-mass PSMA inhibitor...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical chemistry journal Vol. 53; no. 4; pp. 288 - 297
Main Authors: Uspenskaya, A. A., Machulkin, A. É., Mazhuga, A. G., Beloglazkina, E. K.
Format: Journal Article
Language:English
Published: New York Springer US 15-07-2019
Springer
Subjects:
Amino acids
Antigens
Carboplatin
Health aspects
Medicine
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Prostate cancer
targeted delivery
PSMA
drug conjugates
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conjugates for targeted delivery that are based on low-molecular-mass prostate specific membrane antigen (PSMA) inhibitors are widely used and developed because of the deficiencies of existing methods for treating and diagnosing prostate cancer. The major classes of low-molecular-mass PSMA inhibitors, drug classes, and their mechanisms of action are discussed. Therapeutic conjugates for targeted delivery that are based on them are analyzed. Structural features of the linker that affect the biological activity and selectivity are identified.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-019-01994-1